Intensive chemotherapy greatly improved survival for lymphoma patients Oncology Nurse Advisor Groupe d'Etude des Lymphomes de l'Adulte and Amgen funded the open-label randomized trial in which Groupe investigators compared two regimens: dose-intensive rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (R-ACVBP), ... |
